Analyst Information

 

Charles Duncan, PhD

Sr. Research Analyst

Charles Duncan, PhD

Charles Duncan, Ph.D., joined Piper Jaffray in 2012 as a managing director and senior research analyst focused on small- and mid-cap emerging growth biotechnology companies. Duncan has covered the sector since the mid-1990s working previously as an analyst at JMP Securities (since 2000) and also at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the Financial Times and StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. Duncan is a graduate of the University of Wisconsin-Madison and holds a doctorate in pharmaceutical sciences with a concentration in neuropharmacology from the University of Colorado.

Associates:

Sarah Weber
Research Analyst
Universe Coverage:
Healthcare:   Emerging BioPharma
ACADACADIA Pharmaceuticals Inc.
ACORAcorda Therapeutics, Inc.
AIMTAimmune Therapeutics, Inc.
ALDRAlder BioPharmaceuticals, Inc.
ALTAltimmune, Inc.
AXONAxovant Sciences Ltd.
BCRXBioCryst Pharmaceuticals, Inc.
BHVNBiohaven Pharmaceutical Holding Company Ltd
CARACara Therapeutics Inc.
CPRXCatalyst Pharmaceuticals, Inc.
CORTCorcept Therapeutics Inc.
CYTKCytokinetics, Incorporated
DCPHDeciphera Pharmaceuticals, Inc.
GEMPGemphire Therapeutics Inc.
GERNGeron Corporation
HALOHalozyme Therapeutics, Inc.
INOInovio Pharmaceuticals, Inc.
ITCIIntra-Cellular Therapies, Inc.
NBIXNeurocrine Biosciences Inc.
NWRN SWNewron Pharmaceuticals
OTICOtonomy, Inc.
PDLIPDL BioPharma, Inc.
RETAReata Pharmaceuticals, Inc.
SGMOSangamo Therapeutics, Inc.
SPHSSophiris Bio, Inc.
VNDAVanda Pharmaceuticals, Inc.
VBLTVascular Biogenics Ltd.
VYGRVoyager Therapeutics, Inc.
VTVTvTv Therapeutics, Inc.
ZSANZosano Pharma Corporation
ZYNEZynerba Pharmaceuticals, Inc.